

LIVING WITH LUPUS IN 2020

COUNTRY LEVEL DATA

Denmark



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

COUNTRY: Denmark

COUNTRY:	Denmark				
		DEMOGRA	APHICS:		
	<u>Denmark</u>	<u>EUROPE</u>	Age_	<u>Denmark</u>	<u>EUROPE</u>
Total number of responses	110	4375	Up to 25	4.5%	6.4%
			26 to 35	13.6%	17.9%
Gender	<u>Denmark</u>	<u>EUROPE</u>	36 to 45	21.8%	27.4%
Man	4.5%	3.7%	46 to 55	27.3%	26.6%
Woman	94.5%	95.6%	56 to 65	26.4%	14.8%
Other / prefer not to answer	0.9%	0.7%	above 65	3.6%	5.1%
Total	100.0%	100.0%	NA	2.7%	1.8%
			Grand Total	100.0%	100.0%
		DIAGNO	OSIS		
Diagnosis	<u>Denmark</u>	<u>EUROPE</u>	Time to Diagnosis	<u>Denmark</u>	<u>EUROPE</u>
SLE	100.0%	94.4%	Within the year	21.9%	26.5%
Child onset SLE	0.0%	5.6%	1 year	21.0%	21.1%
Grand Total	100.0%	100.0%	2 years	9.5%	11.5%
			3 years	9.5%	5.7%
Prior Diagnosis received before "Lupus"	<u>Denmark</u>	<u>EUROPE</u>	4 years	4.8%	4.6%
None	65.5%	53.7%	5 years	3.8%	4.4%
UCTD/MCTD	1.8%	6.7%	6 years	1.9%	2.9%
Sjogren	1.8%	4.7%	7 years	2.9%	2.7%
APS	5.5%	2.4%	8 years	4.8%	2.4%
Other Autoimmune or Rheumatic	12.7%	13.8%	9 years	1.9%	2.3%
Fibromyalgia	0.0%	5.8%	10 to 20 years	7.6%	10.4%
Psychologic or mental disorder	3.6%	8.9%	More than 20 years	10.5%	5.5%
Other prior diagnosis	17.3%	16.5%	Grand Total	100.0%	100.0%
n=	108	4,275	n=	105	4,154



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

100

n=

4024

			101500000000000000000000000000000000000		
		IMPACT ON STU	JDIES & CAREER		
Education level	<u>Denmark</u>	<u>EUROPE</u>	Employment level	<u>Denmark</u>	EUROPE
Basic	0.0%	3.7%	Employed full time	24.1%	34.6%
Secundary	39.6%	53.9%	Employed part time	25.0%	16.5%
Academic	60.4%	42.5%	Self-employed full time	0.0%	3.0%
n=	106	4,150	Self-employed part time	3.7%	2.4%
			Looking for employment	2.8%	5.1%
Economic profile	<u>Denmark</u>	<u>EUROPE</u>	Stopped work for medical reason	15.7%	14.7%
No difficulties paying all bills	70.0%	46.9%	Retired	19.4%	11.6%
Occasional difficulties paying all bills.	18.2%	26.8%	Student	6.5%	4.0%
Often difficulties paying all bills	3.6%	10.4%	No paid employment / Full time home	0.9%	4.7%
Always difficulty paying all bills	2.7%	7.1%	Other / prefer not to answer	1.9%	3.5%
Did not respond	5.5%	8.9%			
n=	110	4375	n=	108	4247
IMPACT ON STUDIES	<u>Denmark</u>	<u>EUROPE</u>	IMPACT ON CAREER	<u>Denmark</u>	EUROPE
Chose more relevant studies	3.7%	3.1%	No impact	20.0%	32.5%
could not do what they wanted	18.5%	11.1%	Changed career/job	6.0%	13.5%
needed special support and received it	6.5%	4.6%	moved to Flexible hours	1.0%	8.1%
needed support but did NOT receive it	5.6%	2.9%	Reduced Work Schedule	33.0%	18.5%
Overall negative effect	17.6%	13.5%	Stopped work, gets social allowances	31.0%	18.5%
Overall positive effect	0.9%	1.4%	Missed promotion opportunities	9.0%	9.5%
No impact	62.0%	69.8%	Employment was terminated	7.0%	8.4%
			Other negative impact	19.0%	20.8%
n=	108	4240	Other positive impact	1.0%	1.8%
			Overall had negative impact	79.0%	57.9%



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

		IMPACT ON S	OCIAL / FAMILY		
<u>Civil status</u>	Denmark	EUROPE	Have children	<u>Denmark</u>	EUROPE
Child/young with family	3.7%	4.5%	None	25.0%	32.8%
Single	15.0%	17.4%	One child	17.6%	23.8%
Married / with partner	71.0%	66.9%	2 or more children	53.7%	38.9%
Divorced	10.3%	9.2%	Child/young living with family	3.7%	4.5%
Widowed	0.0%	2.0%			
n=	107	4206	n=	108	4288
Would have liked more children	<u>Denmark</u>	<u>EUROPE</u>	Faced Misscariages	<u>Denmark</u>	<u>EUROPE</u>
A. Yes	45.3%	37.6%	A. One miscarriage	16.8%	18.4%
B. No	37.9%	37.7%	B. Some miscarriages	10.5%	8.5%
C. don't know / prefer not to answer	16.8%	24.7%	C. Many miscarriages	1.1%	2.9%
			D. No miscarriage	71.6%	70.2%
n (women only) =	95	3,645	n (women only) =	95	3,756
Difficulty to cope with Daily activities	<u>Denmark</u>	EUROPE	More or less active than others same age	<u>Denmark</u>	<u>EUROPE</u>
No Problem at all 1	8.3%	16.2%	Less active due to lupus	78.5%	72.6%
2	23.1%	32.3%	Equally active	12.1%	15.6%
3	38.9%	34.3%	More active due to lupus	1.9%	3.6%
4	24.1%	15.4%	I don't know	7.5%	8.1%
Fully Unable 5	5.6%	1.8%			
n=	108	4226	n=	107	4212
Impact on Sexual/emotional life	<u>Denmark</u>	<u>EUROPE</u>	Negative Impact on couple	<u>Denmark</u>	<u>EUROPE</u>
Negative impact	43.5%	38.2%	It created tensions	31.6%	33.2%
Mixed Positive and negative	35.2%	36.2%	It is difficult for me	79.7%	68.4%
No significant impact	21.3%	23.9%	It is difficult for my partner	30.4%	26.7%
Positive impact	0.0%	1.6%	I am concerned for my couple	19.0%	13.2%
			Our relationship ended	15.2%	16.6%
n=	108	4,204	n=	79	2875



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

n=

107

4197

			DI	SEASE ACTIVITY		
Lupus was under control past 3 mont	h <u>s</u>	<u>Denmark</u>	<u>EUROPE</u>	Number of symptoms (list of 23)	Denmark	<u>EUROPE</u>
Yes		63%	72%	1	0.9%	1.6%
No		37%	28%	2	0.9%	2.1%
				3		4.4%
	n=	110	4347	4		5.9%
				5	9.3%	6.1%
				6	4.7%	8.5%
		<u>Denmark</u>	<u>EUROPE</u>	7	9.3%	9.3%
Average nr of symptoms (list of 23)		9.1	8.8	8	9.3%	10.4%
	n=	107	4197	9	8.4%	10.1%
				10	8.4%	9.3%
				11	11.2%	8.3%
		<u>Denmark</u>	<u>EUROPE</u>	12	5.6%	7.0%
Median number of symptoms		9	9	13	7.5%	5.8%
	n=	107	4197	14	5.6%	4.4%
				15	2.8%	2.7%
				16	3.7%	2.1%
				17	0.9%	1.1%
				18	0.0%	0.4%
				19	0.9%	0.3%
				20	0.0%	0.0%



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Symptoms or Features experienced / Most bothersome

[Denm	ark_		EURO	<u>OPE</u>
•	<u>Regularly</u>	Top 3 most		Regularly	Top 3 most
Patient reported Symptoms or features	<u>experience</u>	<u>bothersome</u>	Patient reported Symptoms or features	<u>experience</u>	<u>bothersome</u>
A. Rash	51%	10%	A. Rash	40%	9%
B. Sun sensitivity	69%	29%	B. Sun sensitivity	69%	23%
C. Mouth ulcers	39%	4%	C. Mouth ulcers	35%	3%
D. Dryness in the mouth or eyes	52%	11%	D. Dryness in the mouth or eyes	55%	9%
E. Dryness of the skin	57%	4%	E. Dryness of the skin	57%	4%
F. Hair loss	52%	7%	F. Hair loss	53%	14%
G. Pain / swelling in joints	77%	47%	G. Pain / swelling in joints	77%	49%
H. Jaccoud (hand deformation) or tendons a	11%	2%	H. Jaccoud (hand deformation) or tendor	14%	4%
I. Muscle Pain/Weakness	79%	35%	I. Muscle Pain/Weakness	68%	33%
J. Headaches or migraine	51%	9%	J. Headaches or migraine	51%	17%
K. Fatigue and weakness	93%	73%	K. Fatigue and weakness	85%	55%
L. Flu-like symptoms/Fevers	50%	13%	L. Flu-like symptoms/Fevers	28%	4%
M. Shortness of breath	32%	3%	M. Shortness of breath	32%	6%
N. Depression or Anxiety	36%	16%	N. Depression or Anxiety	44%	17%
O. Haematologic problems incl. anemia	21%	2%	O. Haematologic problems incl. anemia	27%	4%
P. Poor circulation or Raynauds	36%	5%	P. Poor circulation or Raynauds	45%	8%
Q. Kidney problems	16%	8%	Q. Kidney problems	20%	11%
R. Chest pain	31%	2%	R. Chest pain	24%	4%
S. High Blood pressure	26%	1%	S. High Blood pressure	23%	4%
T. Stroke, mini-stroke, Blood clots	13%	8%	T. Stroke, mini-stroke, Blood clots	9%	4%
U. Osteoporosis	21%	3%	U. Osteoporosis	19%	5%
n=	110	105	n=	4375	4084



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

			MEDICATION		
Average number of medication (from li	<u>Denmar</u> st	<u>EUROPE</u>	Median number of medication (from	<u>Denmark</u>	<u>EUROPE</u>
of 16)	 5.8	5.2	list of 16)	6	5
	n= 100	5 4099	n=	106	4099
Number of medications (list of 16)	<u>Denmar</u>	<u>EUROPE</u>	% using given medication type:	<u>Denmark</u>	EUROPE
	1 1.9%	6 5.4%	Non Steroids Anti-Inflammatory	25.5%	32.9%
	2 5.7%	6 9.0%	Antimalarials	76.4%	75.0%
	3 13.2%	6 12.5%	Oral Steroids	41.5%	52.4%
	4 9.4%	6 14.1%	Immunosuppressants	57.5%	39.8%
	5 13.2%	4 14.8%	Biologics	11.3%	10.9%
	6 20.8%	6 13.9%	Painkillers	73.6%	50.1%
	7 15.1%	6 11.8%	Antidepressant	15.1%	17.0%
	8 9.4%	6 9.0%	Anxiolytic	3.8%	11.7%
	9 6.6%	6 5.1%	Anticoagulants	24.5%	16.6%
	10 0.9%	6 2.5%	Thyroid medication	10.4%	14.8%
	11 1.9%	6 1.1%	Blood circulation and heart	19.8%	23.3%
	12 0.9%	6 0.4%	Stomach protection	36.8%	47.0%
	13 0.9%	6 0.2%	Statins	10.4%	5.9%
			Calcium	63.2%	29.7%
	n= 100	5 4099	Vitamin D	68.9%	68.4%
			Vitamins (excl.D) / mineral complements	36.8%	25.4%



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

ACCESS / Quality of life (scale of 1 to 5)

I have appropriate access to	<u>Denmark</u>	EUROPE	HrQoL dimensions	<u>Denmark</u>	<u>EUROPE</u>			
Average scores (1 Fully disa	gree - 5 fully agree)		AVERAGE SCORES (1=FULLY ABLE,	AVERAGE SCORES (1=FULLY ABLE, 5= FULLY UNABLE)				
Experienced lupus doctors	4.00	3.81	Mobility	2.27	2.22			
Multidisciplinary team	3.60	3.28	Self care	1.68	1.71			
Specialised nurses that know lupus	3.63	2.92	Daily Activities	2.95	2.54			
Prescribed medication	4.29	4.08	Pain or discomfort	3.10	3.14			
Affordable treatments	3.94	3.77	Anxiety or depression	2.68	2.96			
Social support and benefits	3.24	2.78	Average	2.54	2.51			
Physiotherapy, Rehab, Occupational The	era 3.43	2.77						
Professional psychological support	2.70	2.68						
n m	in 86	3126	n min	108	4196			
n m	ax 103	3842	n max	108	4240			
Worry about lupus progressing?	<u>Denmark</u>	EUROPE						
Very Low (1-2)	3.8%	3.6%						
Low (3-4)	10.6%	9.3%						
Mid (5-6)	20.2%	24.5%						
High (7-8)	50.0%	41.0%						
Very high (9-10)	15.4%	21.6%						
	n= 104	4042						



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Impact of lupus not being under control over past 3 months

	D	<u>enmark</u>		<u>EUROPE</u>		
	<u>lupus un</u>	<u>der</u> <u>not under</u>		lupus under	not under	
	<u>cont</u>	rol control		<u>control</u>	<u>control</u>	
Mobility	7	6% 54%	Mobility	73%	59%	
Self care	8	9% 73%	Self care	86%	73%	
Daily Activities	5	8% 39%	Daily Activities	66%	51%	
Pain or discomfort	5	5% 34%	Pain or discomfort	51%	35%	
Anxiety or depression	5	9% 56%	Anxiety or depression	54%	44%	
Average	6	7% 51%	Average	66%	52%	
n ı	nin	69 39	n min	3011	1179	
n r	nax	69 39	n max	3042	1194	
	<u>D</u>	enmark_		EURO	<u>OPE</u>	
	lupus und	der <u>not under</u>	More or less active than others of same	lupus under	not under	
More or less active than others of same ago	<u>cont</u>	rol control	age	<u>control</u>	<u>control</u>	
Less active due to lupus	73.	5% 87.2%	Less active due to lupus	68.6%	83.0%	
Equally active	13.	2% 10.3%	Equally active	18.8%	7.6%	
More active due to lupus	2.	9% 0.0%	More active due to lupus	4.0%	2.7%	
I don't know	10.	3% 2.6%	I don't know	8.7%	6.7%	
	n=	68 39	n=	3018	1189	
	<u>D</u>	enmark_		EURO	<u>OPE</u>	
	lupus und	der <u>not under</u>		lupus under	not under	
Impact on Sexual/emotional life	<u>cont</u>	rol <u>control</u>	Impact on Sexual/emotional life	control	<u>control</u>	
Negative impact	42.	0% 46.2%	Negative impact	34.0%	49.0%	
Mixed + and -	33.	3% 38.5%	Mixed + and -	36.4%	35.7%	
No significant impact	24.	6% 15.4%	No significant impact	27.8%	14.1%	
Positive impact	0.	0.0%	Positive impact	1.8%	1.2%	
	n=	69 39	n=	3018	1181	



DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

IMPACT OF A PROMPT DIAGNOSIS

% of Health Related QoL Maintained vs 100% = FULL HEALTH/ABILITY TO PERFORM

	<u>Denm</u>	<u>nark</u>		EURC	<u>)PE</u>
		<u>Diagnosed</u>		<u>Diagnosed</u>	<u>Diagnosed</u>
	<u>Diagnosed</u>	after more		within 2	after more
	within 2 years	than 5 years		<u>years</u>	than 5 years
Mobility	76%	59%	Mobility	75%	62%
Self care	86%	77%	Self care	86%	76%
Daily Activities	57%	46%	Daily Activities	67%	53%
Pain or discomfort	53%	39%	Pain or discomfort	52%	39%
Anxiety or depression	59%	61%	Anxiety or depression	52%	49%
Average	66%	57%	Average	66%	56%
Difference		-9%	Difference		-10%
of which - explained by age (*)		-4%	of which - explained by age		-3%
n min	45	35	n min	1926	1239
n max	45	35	n max	1951	1249
average age:	40.6	52.4		41.2	49.0


^(*) in our overall study, we found that from age 28 to age 63 HrQOL drops from 69.1% to 56.0% i.e. 3.7% per decade





DATA FOR: **Denmark**


Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0













DATA FOR: **Denmark**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0







Living with lupus in 2020 - Country level data

DATA FOR: 0

For full text european analysis, please refer to:

Cornet A, Andersen J, Myllys K, et al. Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Science & Medicine 2021;8:e000469. doi:10.1136/lupus-2020-000469

For more informatioin, contact: secretariat@lupus-europe.org